Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 47

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
 and other income, net2,378 270 2,921 1,199 Total other income147,945 3,940 151,390 7,734 Income (loss) before income taxes76,906 (19,855)74,989 (36,547)Income tax expense(2,199)(70)(3,381)— Net income (loss)$74,707 $(19,925)$71,608 $(36,547)Net income (loss) per share of common stock:Basic$1.24 $(0.48)$1.20 $(0.87)Diluted$1.21 $(0.48)$1.16 $(0.87)Weighted-average shares of common stock outstanding:Basic54,780,93841,899,08754,440,10041,839,582Diluted56,324,90341,899,08756,062,44341,839,582

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

Three months ended June 30,Six months ended June 30,2025202420252024Net income (loss)$74,707 $(19,925)$71,608 $(36,547)Other comprehensive (loss) income:Foreign currency translation adjustment(2,346)280 (3,059)464 Other comprehensive (loss) income:(2,346)280 (3,059)464 Comprehensive income (loss)$72,361 $(19,645)$68,549 $(36,083)

See accompanying notes to unaudited condensed consolidated financial statements.

6

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands)

AdditionalTreasuryOtherTotalCommonPaid-inStock,AccumulatedComprehensiveStockholders'StockCapitalat costDeficitIncome (Loss)EquityBalance as of January 1, 2025$5 $555,302 $(10,983)$(505,289)$631 $39,666 Net loss— — — (3,099)— (3,099